Free Trial

Applied Therapeutics (APLT) Stock Forecast & Price Target

$7.85
+3.20 (+68.82%)
(As of 09/18/2024 ET)

Applied Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 6 Wall Street analysts who have issued ratings for Applied Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 5 have given a buy rating, and 1 has given a strong buy rating for APLT.

Consensus Price Target

$11.25
43.31% Upside
High Forecast$13.00
Average Forecast$11.25
Low Forecast$8.00

According to the 6 analysts' twelve-month price targets for Applied Therapeutics, the average price target is $11.25. The highest price target for APLT is $13.00, while the lowest price target for APLT is $8.00. The average price target represents a forecasted upside of 43.31% from the current price of $7.85.

TypeCurrent Forecast
9/19/23 to 9/18/24
1 Month Ago
8/20/23 to 8/19/24
3 Months Ago
6/21/23 to 6/20/24
1 Year Ago
9/19/22 to 9/19/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.25$11.00$11.00$9.50
Forecasted Upside43.31% Upside101.56% Upside103.42% Upside949.03% Upside

APLT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

APLT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Applied Therapeutics Stock vs. The Competition

TypeApplied TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.17
2.77
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside43.31% Upside1,005.12% Upside7.87% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/30/2024William Blair
2 of 5 stars
L. Hanbury-Brown
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/27/2024Citigroup
3 of 5 stars
 Boost TargetBuy ➝ Buy$7.00 ➝ $8.00+34.91%
7/17/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.00+112.01%
3/15/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$12.00 ➝ $13.00+109.00%
2/22/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Schwartz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/22/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$12.00+133.92%
4/25/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$18.00 ➝ $14.00+1,172.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:47 PM ET.

APLT Forecast - Frequently Asked Questions

What is Applied Therapeutics' forecast for 2024?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Applied Therapeutics is $11.25, with a high forecast of $13.00 and a low forecast of $8.00.

Should I buy or sell Applied Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" APLT shares.

Does Applied Therapeutics's stock price have much upside?

According to analysts, Applied Therapeutics's stock has a predicted upside of 96.16% based on their 12-month stock forecasts.

Has Applied Therapeutics been upgraded by Wall Street analysts recently?

Over the previous 90 days, Applied Therapeutics's stock had 1 upgrade by analysts.

What analysts cover Applied Therapeutics?

Applied Therapeutics has been rated by research analysts at Citigroup, Royal Bank of Canada, and William Blair in the past 90 days.

Do Wall Street analysts like Applied Therapeutics more than its competitors?

Analysts like Applied Therapeutics more than other "medical" companies. The consensus rating for Applied Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how APLT compares to other companies.



This page (NASDAQ:APLT) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners